Zhuhai, China

Fan Wu

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Biotheus Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fan Wu. Retrieved from https://idiyas.com/inventor/fan-wu-udkpyz7h

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fan Wu: Innovator in Antibody Development

Introduction

Fan Wu is a prominent inventor based in Zhuhai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work is crucial in advancing therapeutic options for various diseases.

Latest Patents

Fan Wu holds a patent for an "ANTI-PD-L1 AND PD-L2 ANTIBODY AND DERIVATIVES AND USE THEREOF." This innovative patent highlights his expertise in creating antibodies that target specific proteins involved in immune response regulation.

Career Highlights

Fan Wu is currently employed at Biotheus Inc., a company dedicated to developing innovative biopharmaceuticals. His role at Biotheus Inc. allows him to leverage his skills and knowledge in antibody research to contribute to groundbreaking therapies.

Collaborations

He has collaborated with notable colleagues, including Xiaoniu Miao and Cheng Chen. These partnerships enhance the research and development efforts at Biotheus Inc., fostering a collaborative environment for innovation.

Conclusion

Fan Wu's contributions to antibody development exemplify the impact of innovative research in biotechnology. His work continues to pave the way for advancements in therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…